<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1307">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01786707</url>
  </required_header>
  <id_info>
    <org_study_id>IND 13724</org_study_id>
    <nct_id>NCT01786707</nct_id>
  </id_info>
  <brief_title>Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus</brief_title>
  <acronym>HOT</acronym>
  <official_title>Phase 2 Study of Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rodolfo Alejandro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open labeled, randomized controlled clinical trial comparing the benefit of
      both hyperbaric oxygen therapy and intrapancreatic stem cell infusion to standard medical
      treatment alone for type 2 diabetes mellitus. Subjects will receive standard medical
      treatment (SMT) with insulin and metformin for 4 months (evaluation phase). Then they will
      be randomized into either the intervention group or the control group:
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I/II, prospective, randomized case controlled study in patients with Type 2
      Diabetes Mellitus (T2DM) that seeks to investigate whether the combination of
      intrapancreatic Autologous Stem Cell infusion (ASC) and Hyperbaric Oxygen treatment (HBO)
      can improve glycemic control and pancreatic function in T2DM patients compared to controls
      receiving standard medical treatment (SMT) with metformin and insulin alone.

      New therapies that lead to stopping ß-cell damage and possible ß-cell regeneration may
      decrease the incidence and progression of T2DM chronic complications and together with
      achievable life style changes may improve general health and quality of life of T2DM
      patients. Preliminary data from a pilot study involving 25 subjects with T2DM that underwent
      a combined treatment using ASC+HBO showed a significant progressive and consistent reduction
      in plasma glucose and HbA1c with an increase in C-peptide in conjunction with a decrease in
      the number and dose of oral agents and/or insulin. These encouraging preliminary results
      require confirmation in a controlled, randomized prospective trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>The Reduction in HbA1c From Time of Randomization to 1 Year After Intervention.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Subjects With a Reduction of &gt;1% in HbA1c</measure>
    <time_frame>at 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Autologous SC and HOT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous stem cells and hyperbaric oxygen therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in a control group will continue with standard medical treatment (SMT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous stem cells and hyperbaric oxygen therapy</intervention_name>
    <description>Subjects will receive standard medical treatment (SMT) with insulin and metformin for 4 months. Then they will be randomized to either control or intervention groups. HOT and SC group: combination of HOT therapy and intrapancreatic autologous SC infusion in addition to SMT.</description>
    <arm_group_label>Autologous SC and HOT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients age 45 to 65 years of age.

          2. Ability to provide written informed consent.

          3. Mentally stable and able to comply with the procedures of the study protocol.

          4. Clinical history compatible with type 2 diabetes as defined by the Expert Committee
             on the Diagnosis and classification of Diabetes Mellitus.

          5. Onset of T2DM disease at 40 years of age.

          6. T2DM duration: 2-15 years at the time of enrollment.

          7. Basal C-peptide: 0.3 ng/mL

          8. HbA1c of 7.5-12.5% before standard medical therapy. Patients must have been treated
             with SMT for minimum of 4 months prior to randomization. Insulin and metformin doses
             should be stable over the 3 months prior to randomization.

          9. HbA1c: 7.5-9.5% at time of randomization.

         10. Total insulin daily dose at baseline and at randomization &lt;100 units/day.

        Exclusion Criteria:

          1. BMI &gt;40 kg/m2.

          2. Insulin requirements of &gt;100 U/day, and HbA1c &gt;9.5%

          3. C-reactive protein &gt;10.00

          4. Uncontrolled blood pressure: SBP &gt;140 mmHg or DBP &gt;80 mmHg Evidence of renal
             dysfunction, serum creatinine &gt; 1.5 mg/dl (males) and 1.4 mg/dl (females)

          5. Proteinuria &gt;300 mg/day

          6. History or EKG evidence of myocardial infarction or any degree of heart failure

          7. Female participants: Positive pregnancy test, presently breast-feeding, or
             unwillingness to use effective contraceptive measures for the duration of the study.
             Male participants: intent to procreate 3 months before or after the intervention or
             unwillingness to use effective measures of contraception.

          8. Active infection including hepatitis B, hepatitis C, HIV, or TB. Positive tests are
             acceptable only if associated with a history of previous vaccination in the absence
             of any sign of active infection.

          9. Known active alcohol or substance abuse including cigarette/cigar smoking

         10. Baseline Hgb below the lower limits of normal at the local laboratory; lymphopenia
             (&lt;1,000/L), neutropenia (&lt;1,500/L), or thrombocytopenia (platelets &lt;100,000/L).

         11. A history of Factor V deficiency or other coagulopathy defined by INR &gt;1.5, PTT &gt;40,
             PT &gt;15.

         12. Acute or chronic pancreatitis.

         13. Symptomatic peptic ulcer disease.

         14. Hyperlipidemia despite medical therapy

         15. Receiving treatment for a medical condition requiring chronic use of systemic
             corticosteroids in the past six months.

         16. Symptomatic cholecystolithiasis.

         17. Use of any investigational agents within 4 weeks of enrollment.

         18. Admission to hospital for any reason in the 14 days prior to enrollment.

         19. History or presence of active proliferative diabetic retinopathy or macular edema.

         20. Any malignancy.

         21. Hepatic enzyme levels upper normal limits.

         22. Total bilirubin upper normal limits unless secondary to known benign condition.

         23. Abdominal aortic aneurysm.

         24. History of cerebro-vascular accident.

         25. Any patient with acute or subacute decompensation from diabetes.

         26. Any acute or chronic infectious condition that in the criteria of the investigator
             would be a risk for the patient.

         27. Hypoproteinemia, cachexia or terminal states; history of anorexia/bulimia;
             respiratory insufficiency; history of chronic sinusitis (sinusitis lasting more than
             8 weeks in the past year) or recurrent acute sinusitis (sinusitis lasting more than 4
             weeks more than four times in the past year.

         28. Any contraindication to hyperbaric oxygen treatment.

         29. Subjects treated with any medication that could interfere with the outcome of the
             study.

         30. Subjects positive for auto-antibodies

         31. History of Cushing syndrome (endogenous or iatrogenic).

         32. History of allergy to iodine or iodinated materials.

         33. Abnormal thyroid function

         34. Any medical condition that, in the opinion of the investigator, will interfere with
             the safe completion of the trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodolfo Alejandro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Research Institute, University of Miami Miller School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Research Institute, University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 18, 2014</lastchanged_date>
  <firstreceived_date>February 5, 2013</firstreceived_date>
  <firstreceived_results_date>December 20, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Rodolfo Alejandro</investigator_full_name>
    <investigator_title>Director, Clinical Islet Transplant Program, Diabetes Research Institute</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Hyperbaric oxygen therapy (HOT)</keyword>
  <keyword>Autologous Bone Marrow-Derived Buffy Coat</keyword>
  <keyword>Stem cells (SC)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Autologous SC and HOT</title>
          <description>Autologous stem cells and hyperbaric oxygen therapy
Autologous stem cells and hyperbaric oxygen therapy: Subjects will receive standard medical treatment (SMT) with insulin and metformin for 4 months. Then they will be randomized to either control or intervention groups. HOT and SC group: combination of HOT therapy and intrapancreatic autologous SC infusion in addition to SMT.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Patients in a control group will continue with standard medical treatment (SMT)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Autologous SC and HOT</title>
          <description>Autologous stem cells and hyperbaric oxygen therapy
Autologous stem cells and hyperbaric oxygen therapy: Subjects will receive standard medical treatment (SMT) with insulin and metformin for 4 months. Then they will be randomized to either control or intervention groups. HOT and SC group: combination of HOT therapy and intrapancreatic autologous SC infusion in addition to SMT.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Patients in a control group will continue with standard medical treatment (SMT)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Reduction in HbA1c From Time of Randomization to 1 Year After Intervention.</title>
        <time_frame>1 year</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Autologous SC and HOT</title>
            <description>Autologous stem cells and hyperbaric oxygen therapy
Autologous stem cells and hyperbaric oxygen therapy: Subjects will receive standard medical treatment (SMT) with insulin and metformin for 4 months. Then they will be randomized to either control or intervention groups. HOT and SC group: combination of HOT therapy and intrapancreatic autologous SC infusion in addition to SMT.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients in a control group will continue with standard medical treatment (SMT)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Reduction in HbA1c From Time of Randomization to 1 Year After Intervention.</title>
            <units>reduction of A1c</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.4"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Subjects With a Reduction of &gt;1% in HbA1c</title>
        <time_frame>at 6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Autologous SC and HOT</title>
          <description>Autologous stem cells and hyperbaric oxygen therapy
Autologous stem cells and hyperbaric oxygen therapy: Subjects will receive standard medical treatment (SMT) with insulin and metformin for 4 months. Then they will be randomized to either control or intervention groups. HOT and SC group: combination of HOT therapy and intrapancreatic autologous SC infusion in addition to SMT.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Patients in a control group will continue with standard medical treatment (SMT)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Rodolfo Alejandro</name_or_title>
      <organization>University of Miami School of Medicine</organization>
      <phone>3052435324</phone>
      <email>ralejand@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
